logo-loader
viewMaxCyte Inc

MaxCyte Inc 'demonstrating outstanding progress' as first half revenues climb 30%

Proactive Research analyst Emma Ulker discusses MaxCyte Inc's (LON:MXCT) first half trading update in which it revealed revenues grew by 30% to US$10.9mln and that its research and development operation's expected to be self-funded by the end of the year. Ulker says trading reflected the solid progress made in their cell therapy business which is focused on driving adoption of its non-viral cell engineering technology Flow Electroporation across its ExPERT instrument platform.

Quick facts: MaxCyte Inc

Price: 310 GBX

AIM:MXCT
Market: AIM
Market Cap: £239.2 m
Follow

Add related topics to MyProactive

Create your account: sign up and get ahead on news and events

NO INVESTMENT ADVICE

The Company is a publisher. You understand and agree that no content published on the Site constitutes a recommendation that any particular security, portfolio of securities, transaction, or investment strategy is...

In exchange for publishing services rendered by the Company on behalf of MaxCyte Inc named herein, including the promotion by the Company of MaxCyte Inc in any Content on the Site, the Company receives from said...

FOR OUR FULL DISCLAIMER CLICK HERE

Watch

Maxcyte deal with APEIRON Biologics 'highlights value of its Flow...

Proactive Research analyst Emma Ulker discusses MaxCyte’s (LON:MXCT) new clinical and commercial licence agreement with Apeiron Biologics. It allows the use of MaxCyte’s proprietary Flow Electroporation technology for manufacturing Apeiron’s gene-silencing siRNA therapy, APN401, for clinical...

on 8/7/20

2 min read